+Compare
ALRN
Stock ticker:
NASDAQ
AS OF
Jun 29 closing price
Price
$0.30
Change
-$0.11 (-26.83%)
Capitalization
37.42M

ALRN Price Prediction, Aileron Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 29, 2022

Momentum Indicator for ALRN turns negative, indicating new downward trend

ALRN saw its Momentum Indicator move below the 0 level on June 29, 2022. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 80 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ALRN turned negative on June 29, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ALRN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 74 cases where ALRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALRN advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 138 cases where ALRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.755) is normal, around the industry mean (24.945). P/E Ratio (0.000) is within average values for comparable stocks, (95.066). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.895). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.082).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

ALRN is expected to report earnings to rise 3.67% to -9 cents per share on August 09

Aileron Therapeutics ALRN Stock Earnings Reports
Q2'22
Est.
$-0.09
Q1'22
Missed
by $0.01
Q4'21
Est.
$-0.08
Q3'21
Est.
$-0.07
Q2'21
Beat
by $0.01
The last earnings report on May 05 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 3.36M shares outstanding, the current market capitalization sits at 37.42M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Global Blood Therapeutics (NASDAQ:GBT), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.71B. The market cap for tickers in the group ranges from 2.5K to 249.19B. NONOF holds the highest valuation in this group at 249.19B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 208%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 136%. For the same stocks of the Industry, the average monthly volume growth was 135% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: -1 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of stapled peptide drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
285 Summer Street
Phone
+1 617 995-0900
Employees
9
Web
https://www.aileronrx.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCSI44.870.60
+1.36%
Consensus Cloud Solutions
MTD1146.0215.25
+1.35%
Mettler-Toledo International
PK13.73-0.32
-2.28%
Park Hotels & Resorts
UONE5.60-0.19
-3.28%
Urban One
CHEK0.31-0.02
-6.10%
Check-Cap Ltd

ALRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALRN has been loosely correlated with CFRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ALRN jumps, then CFRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALRN
1D Price
Change %
ALRN100%
-27.14%
CFRX - ALRN
45%
Loosely correlated
+3.94%
TFFP - ALRN
44%
Loosely correlated
N/A
HEPA - ALRN
42%
Loosely correlated
-11.14%
ONTX - ALRN
41%
Loosely correlated
-1.48%
GLYC - ALRN
41%
Loosely correlated
+1.23%
More